In a significant development for the global pharmaceutical sector, AstraZeneca’s leading executive in China, Leon Wang, has been detained by Chinese authorities, marking an escalation in the ongoing probe into
In a significant development for the global pharmaceutical sector, AstraZeneca’s leading executive in China, Leon Wang, has been detained by Chinese authorities, marking an escalation in the ongoing probe into
AstraZeneca, one of the world's leading pharmaceutical companies, experienced a significant setback on Tuesday as its stock price plummeted, wiping out £15 billion in market value. This dramatic drop was triggered by a combination of disappointing early data on its weight loss drug candidate and reports of a major fraud case involving company executives in China. Let's delve into the details of these developments and their potential implications for AstraZeneca's future.
In a world where numerous industries are reevaluating the transformative potential of artificial intelligence (AI), the pharmaceutical sector is already experiencing revolutionary changes in drug discovery. Companies like GSK and
The fate of AstraZeneca’s planned £450 million investment in a vaccine manufacturing facility in northwest England hangs in the balance as the Treasury, under the leadership of Chancellor Rachel Reeves,






